Global Chronic Obstructive Pulmonary Disease Market
Report Highlights
Chronic Obstructive Pulmonary Disease MarketSize And Forecast
According to Verified Market Research, the Chronic Obstructive Pulmonary Disease Market was valued at USD 10.17 Billion in 2018 and is projected to reach USD 13.9 Billion by 2026, growing at a CAGR of 4.03% from 2019 to 2026.
Global Chronic Obstructive Pulmonary Disease Market Outlook
The high prevalence of chronic respiratory diseases, new product launches and technological advancements, and rising demand for home care therapeutics devices are some factors that are expected to boom the growth of global chronic obstructive pulmonary disease market. The increasing number of product approvals from FDA has also helped in market growth. For instance, in April 2019, Circassia Pharmaceuticals plc, announced that they have received FDA approval for Duaklir, that is specially designed for the treatment of COPD. However, the high cost of COPD treatment, increasing problem associated with patent expiry, and the dearth of awareness and knowledge among population about COPD symptoms and indications are some factors that might restrict the market growth.
Global Chronic Obstructive Pulmonary Disease Market Competitive Landscape
The Global Chronic Obstructive Pulmonary Disease Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as AstraZeneca, Astellas Pharma Inc., Abbott Laboratories, GlaxoSmithKline plc., Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Circassia Pharmaceuticals, Pfizer, Inc., and Almirall.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.